Covid-19: Swissmedic adapts Inspections
Recommendation

27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
Owing to the new situation regarding the COVID-19 pandemic and the differing measures introduced by the various cantons, Swissmedic has decided to adapt the way it carries out inspections. Inspections in the healthcare field will only be performed after prior clarification of possible COVID-19-related capacity problems.
The inspections may be carried out while observing the recommended protective measures - either (partly) by means of remote assessments or at a later point in time. Safety assessments - whether non-routine and scheduled and "for cause", or routine and scheduled but process-specific - will generally take place on site. If inspections are carried out on site, participants must organise the necessary safety precautions for the inspections (meeting rooms with sufficient space, restricted participant numbers, provision of electronic resources such as projectors for document assessment, plus face masks, sanitisers, etc.).
Source: Swissmedic
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development


